Published Healthcare & Pharmaceuticals Novel antibiotics We have developed lead BPL antagonist BPL199, which is active against Staphylococcus aureus BPL and Mycobacterium tuberculosis with > 44m-fold less selectivity for human BPL. By University of Adelaide
Do you have an innovative technology, product or service? Add your solution to the world’s most advanced open innovation platform and get seen by global corporations seeking new solutions – all free of charge.
